HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inhibition of thrombin (factor IIa) and activated factor X (factor Xa), and to a lesser extent factors IXa, XIa, and XIIa, thereby preventing thrombus formation and extension.
| Metabolism | Heparin is metabolized by the liver and reticuloendothelial system. It is partially desulfated and depolymerized; some components are excreted unchanged in urine. Metabolism is dose-dependent and saturable at high doses. |
| Excretion | Renal (primarily via saturable mechanism; small amount metabolized by liver and reticuloendothelial system; no biliary/fecal elimination of significance) |
| Half-life | Mean 1-2 hours (dose-dependent: increases with dose due to saturable clearance; at 100 U/kg IV: ~1 hr; at 400 U/kg: ~2.5 hrs); clinical context: may be prolonged in hepatic/renal disease |
| Protein binding | Very high, ~95-98% (binds to antithrombin III, albumin, and other plasma proteins) |
| Volume of Distribution | 0.05-0.1 L/kg (confined to plasma volume; low Vd due to high protein binding and large molecular size) |
| Bioavailability | SC: 20-30% (variable based on injection site and depth); IV: 100% |
| Onset of Action | IV: immediate; SC: 20-30 minutes |
| Duration of Action | IV: 2-6 hours (dose-dependent); SC: 8-12 hours; clinical notes: effect can be reversed with protamine; monitoring aPTT required |
| Molecular Weight | 15000 |
IV: Initial bolus of 80 units/kg, then 18 units/kg/hour continuous infusion. Adjust based on aPTT. Typical maintenance: 1300 units/hour for adult (70 kg).
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose adjustment required; monitor aPTT and adjust accordingly. Accumulation not significant due to large molecular weight and extensive protein binding. |
| Liver impairment | No specific Child-Pugh based modifications. Heparin clearance may be reduced in severe hepatic impairment; monitor coagulation parameters closely. |
| Pediatric use | IV: Bolus 75-100 units/kg over 10 minutes, then continuous infusion: Infants: 28 units/kg/hour; Children >1 year: 20 units/kg/hour; Adolescents: 18 units/kg/hour. Titrate to target aPTT (usually 60-85 seconds). |
| Geriatric use | Elderly patients (≥65 years) may have reduced heparin clearance; use lower initial infusion rates (e.g., 15 units/kg/hour) and monitor aPTT frequently to avoid over-anticoagulation. |
| 1st trimester | Heparin does not cross the placenta and is considered safe in pregnancy. No increased risk of fetal malformations has been observed. |
| 2nd trimester | Safe for use; no teratogenic effects reported. Monitor for maternal hemorrhage. |
| 3rd trimester | Safe for use; may be preferred over warfarin for venous thromboembolism prophylaxis or treatment near term. Risk of maternal bleeding and osteoporosis with prolonged use. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Heparin does not cross the placenta due to its high molecular weight and negative charge. |
| Breastfeeding | Heparin is not excreted into breast milk due to its high molecular weight and poor oral bioavailability, thus considered safe during breastfeeding. |
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Heparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations reported. Risk of hemorrhage at delivery. |
| Fetal Monitoring | Monitor maternal platelet count (risk of heparin-induced thrombocytopenia), activated partial thromboplastin time (aPTT), signs of bleeding, and fetal surveillance (ultrasound for growth, nonstress test) if used in pregnancy. |
| Fertility Effects | No known adverse effects on fertility based on available data. |
■ FDA Black Box Warning
Heparin is not intended for intramuscular use. There is an increased risk of bleeding complications. Monitor platelet counts regularly; heparin-induced thrombocytopenia (HIT) can occur. Use with caution in patients with history of HIT. Preservative-free heparin should be used in neonates and infants.
| Common Effects | fluid replacement |
| Serious Effects |
History of heparin-induced thrombocytopenia (HIT)Active major bleedingSevere thrombocytopenia (platelet count <50,000/μL)Hypersensitivity to heparin or pork productsUncontrolled bleeding disorder (e.g., hemophilia)
| Precautions | Monitor for signs of bleeding (hematuria, melena, easy bruising, epistaxis, etc.), Heparin-induced thrombocytopenia (HIT) and heparin-induced thrombocytopenia with thrombosis (HITTS): discontinue heparin immediately if HIT suspected, Epidural or spinal catheter use: risk of spinal or epidural hematoma with concurrent anticoagulants, Hyperkalemia due to aldosterone suppression (especially in elderly, diabetic, renally impaired), Osteoporosis with prolonged use (>1 month), Hypersensitivity reactions including urticaria, angioedema, anaphylaxis |
| Food/Dietary | No significant food interactions. However, avoid excessive intake of foods high in vitamin K (e.g., leafy green vegetables, broccoli, Brussels sprouts) unless consistent consumption pattern is maintained, as vitamin K can antagonize heparin's effect indirectly. Alcohol may increase bleeding risk and should be limited. |
| Clinical Pearls | Heparin sodium 10,000 units in 0.45% sodium chloride is a high-concentration infusion typically used for continuous intravenous administration in acute thrombotic events or prophylaxis. Confirm compatibility with all IV lines and medications; avoid concurrent use with other anticoagulants without clear indication. Monitor aPTT closely, targeting 1.5-2.5 times control for therapeutic effect. Rapid reversal requires protamine sulfate (1 mg per 100 units heparin). Use with caution in renal impairment, elderly, and patients with history of heparin-induced thrombocytopenia (HIT). Check platelet counts every 2-3 days to detect HIT early. Weight-based dosing is standard; this formulation is often used for bolus administration or infusion in fluid-restricted patients. |
| Patient Advice | You will receive this medication through an IV line to prevent or treat blood clots. · You may experience bruising or bleeding more easily; report any unusual bleeding, dark stools, or blood in urine immediately. · Avoid taking aspirin, ibuprofen, or other NSAIDs unless prescribed by your doctor, as they increase bleeding risk. · Inform all healthcare providers (including dentists) that you are taking heparin. · Do not discontinue the medication suddenly; it will be tapered as directed by your doctor. · You may be required to have regular blood tests (aPTT, platelet count) to monitor the drug's effect. · Notify your doctor immediately if you develop chest pain, shortness of breath, or signs of allergic reaction (rash, difficulty breathing). |
Loading safety data…